Assignee
CANCER RESEARCH TECH LTD
GB·82 granted patents·54 pending applications·159 citations·filing 2014–2025
Top patents by PatentIndex Score
136 records- 0193US11897877B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2021·Granted Feb 13, 2024·2 cites·17 claims
- 0293US9932344B2Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic useCANCER RESEARCH TECH LTD·Filed 2015·Granted Apr 3, 2018·12 cites·30 claims
- 0392US11680068B2Compounds useful as RET inhibitorsCANCER RESEARCH TECH LTD·Filed 2022·Granted Jun 20, 2023·1 cites·14 claims
- 0491US9890157B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted Feb 13, 2018·10 cites·15 claims
- 0591US9834552B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted Dec 5, 2017·8 cites·8 claims
- 0690US11352361B2Compounds useful as RET inhibitorsCANCER RESEARCH TECH LTD·Filed 2018·Granted Jun 7, 2022·3 cites·22 claims
- 0789US11766434B2Pyrimidinone derivatives as CDC7 inhibitorsCANCER RESEARCH TECH LTD·Filed 2021·Granted Sep 26, 2023·2 cites·19 claims
- 0889US10954241B2Heterocyclic compounds as ret kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Mar 23, 2021·3 cites·29 claims
- 0989US10640819B2Method for detecting a genetic variantCANCER RESEARCH TECH LTD·Filed 2015·Granted May 5, 2020·13 cites·20 claims
- 1088US11046688B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2019·Granted Jun 29, 2021·2 cites·19 claims
- 1188US10927119B2Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic useCANCER RESEARCH TECH LTD·Filed 2019·Granted Feb 23, 2021·3 cites·26 claims
- 1288US10844067B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Nov 24, 2020·4 cites·27 claims
- 1388US10414726B2Therapeutic agentsCANCER RESEARCH TECH LTD·Filed 2017·Granted Sep 17, 2019·6 cites·19 claims
- 1487US11548896B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2021·Granted Jan 10, 2023·1 cites·30 claims
- 1587US10414772B2Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic useCANCER RESEARCH TECH LTD·Filed 2018·Granted Sep 17, 2019·4 cites·29 claims
- 1686US11512095B2BCL6 inhibitorsCANCER RESEARCH TECH LTD·Filed 2019·Granted Nov 29, 2022·7 cites·20 claims
- 1786US10479788B2Compounds that inhibit MPS1 kinaseCANCER RESEARCH TECH LTD·Filed 2018·Granted Nov 19, 2019·4 cites·19 claims
- 1886US9902721B2N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitorsCANCER RESEARCH TECH LTD·Filed 2015·Granted Feb 27, 2018·7 cites·13 claims
- 1985US11661423B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2020·Granted May 30, 2023·1 cites·24 claims
- 2085US10189821B2Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor ICANCER RESEARCH TECH LTD·Filed 2016·Granted Jan 29, 2019·5 cites·14 claims
- 2185US2025236624A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 2284US12129236B2PARG inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2021·Granted Oct 29, 2024·1 cites·14 claims
- 2384US11124501B2Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor ICANCER RESEARCH TECH LTD·Filed 2018·Granted Sep 21, 2021·2 cites·21 claims
- 2484US10995073B2PARG inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2019·Granted May 4, 2021·3 cites·16 claims
- 2583US11787792B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RESEARCH TECH LTD·Filed 2020·Granted Oct 17, 2023·1 cites·21 claims
- 2683US10508086B2PARG inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2015·Granted Dec 17, 2019·3 cites·12 claims
- 2782US11098121B2“Immune checkpoint intervention” in cancerCANCER RESEARCH TECH LTD·Filed 2016·Granted Aug 24, 2021·4 cites·25 claims
- 2882US10399974B2N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitorsCANCER RESEARCH TECH LTD·Filed 2018·Granted Sep 3, 2019·3 cites·4 claims
- 2982US2025223266A1Parg inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 3082US2025243202A1Compounds Useful as RET InhibitorsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 3181US10577354B2Bis-pyridazine compounds and their use in treating cancerCANCER RESEARCH TECH LTD·Filed 2019·Granted Mar 3, 2020·2 cites·20 claims
- 3281US2024254110A1Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1CANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 3381US2024132504A1Compounds Useful as RET InhibitorsCANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 3480US11161839B22-quinolone derived inhibitors of BCL6CANCER RESEARCH TECH LTD·Filed 2018·Granted Nov 2, 2021·4 cites·19 claims
- 3580US10821194B2Labelled carboxylic acids and their uses in molecular imagingCANCER RESEARCH TECH LTD·Filed 2019·Granted Nov 3, 2020·2 cites·27 claims
- 3680US10501462B2Pyrrolo[3,2-c]pyridine-6-amino derivativesCANCER RESEARCH TECH LTD·Filed 2016·Granted Dec 10, 2019·3 cites·10 claims
- 3779US12109184B2Personalized methods of treating cancerCANCER RESEARCH TECH LTD·Filed 2021·Granted Oct 8, 2024·1 cites·19 claims
- 3879US12042477B2Dietary product devoid of at least two non essential amino acidsCANCER RESEARCH TECH LTD·Filed 2017·Granted Jul 23, 2024·2 cites·22 claims
- 3978US11020396B2Pyrimidinone derivatives as Cdc7 inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Jun 1, 2021·2 cites·20 claims
- 4078US10259806B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RESEARCH TECH LTD·Filed 2017·Granted Apr 16, 2019·2 cites·16 claims
- 4178US2023339954A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2022·Application pending·0 cites
- 4278US2026042776A1Bcl6 inhibitorsCANCER RESEARCH TECH LTD·Filed 2025·Application pending·0 cites
- 4377US11919959B2Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesisCANCER RESEARCH TECH LTD·Filed 2020·Granted Mar 5, 2024·1 cites·4 claims
- 4477US10981904B21,3,4-thiadiazole compounds and their use in treating cancerCANCER RESEARCH TECH LTD·Filed 2019·Granted Apr 20, 2021·1 cites·18 claims
- 4576US2024116938A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 4675US11787786B2Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1CANCER RESEARCH TECH LTD·Filed 2021·Granted Oct 17, 2023·0 cites·1 claims
- 4775US10654846B2Autotaxin inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted May 19, 2020·2 cites·2 claims
- 4875US10647678B2Quinoline derivatives as inhibitors of heat shock factor 1 pathway activityCANCER RESEARCH TECH LTD·Filed 2016·Granted May 12, 2020·3 cites·18 claims
- 4975US9820976B21-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapyCANCER RESEARCH TECH LTD·Filed 2016·Granted Nov 21, 2017·1 cites·30 claims
- 5073US11001638B2Immunomodulatory antibodiesCANCER RESEARCH TECH LTD·Filed 2016·Granted May 11, 2021·1 cites·4 claims
Showing the top 50 of 136 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CANCER RESEARCH TECH LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →